Mettler-Toledo (MTD) Stock Chart - Revenue & Earnings | Quarter Chart
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Mettler-Toledo (MTD) quarterly earnings & revenue
Mettler-Toledo (MTD) reported revenue of $947.13M for Q1 2026, up 7.2% year-over-year, with net income of $169.45M and diluted EPS of $8.35.
Over the last four reported quarters, Mettler-Toledo generated $4.09B in revenue and $875.06M in net income.
Mettler-Toledo's next earnings report is scheduled for July 30, 2026 after market close; analysts estimate EPS of $10.78.
Mettler-Toledo quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q1 2026 | $947.13M | +7.2% | $169.45M | $8.35 |
| Q4 2025 | $1.13B | +8.1% | $285.76M | $14.02 |
| Q3 2025 | $1.03B | +7.9% | $217.49M | $10.57 |
| Q2 2025 | $983.22M | +3.9% | $202.35M | $9.77 |
| Q1 2025 | $883.74M | -4.6% | $163.59M | $7.84 |
| Q4 2024 | $1.05B | +11.8% | $252.30M | $11.96 |
| Q3 2024 | $954.53M | +1.3% | $211.52M | $9.94 |
| Q2 2024 | $946.75M | -3.6% | $221.81M | $10.37 |
Mettler-Toledo (MTD) — frequently asked questions
When does Mettler-Toledo (MTD) report earnings next?
Mettler-Toledo is expected to report earnings on July 30, 2026 after market close. Analysts estimate EPS of $10.78.
What was MTD's revenue last quarter?
Mettler-Toledo reported revenue of $947.13M in Q1 2026, up 7.2% from the same quarter a year earlier.
What was MTD's EPS last quarter?
Mettler-Toledo reported diluted EPS of $8.35 in Q1 2026.
Is Mettler-Toledo profitable?
Mettler-Toledo is currently profitable, with $875.06M in net income over the last four reported quarters.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)